Loading
Dementia / Snoezelen Multisensory Therapy / Standard Therapy · Interventional Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed but unpublished registry record of a randomized controlled trial comparing Snoezelen Multisensory Therapy plus standard care versus standard care alone in 63 older adults with dementia. No outcome data are reported in this registry entry, so the efficacy or safety of the intervention cannot be evaluated.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Dementia; age from 65 Years. Intervention: SMT + Standard Therapy. Compared with: Standard Therapy Only — Active Comparator. n = 63. 1 site: Slovenia.
This is a completed but unpublished registry record of a randomized controlled trial comparing Snoezelen Multisensory Therapy plus standard care versus standard care alone in 63 older adults with dementia. No outcome data are reported in this registry entry, so the efficacy or safety of the intervention cannot be evaluated.
Results not posted in registry record; no efficacy or safety data available for interpretation.
The source did not state who this applies to in practice.
Registry record of a completed interventional trial with no results posted; the design is sound but outcomes remain unreported, precluding evidence assessment.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07657208). This is a study registration, not published results. Lead sponsor: University of Primorska. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 63 participants (ACTUAL). Conditions: Dementia. Interventions: BEHAVIORAL: Snoezelen Multisensory Therapy; BEHAVIORAL: Standard Therapy. Primary outcome measures: Change in agitation level as measured by Cohen-Mansfield Agitation Inventory (CMAI) , Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12; Change in depressive symptoms as measured by Cornell Scale for Depression in Dementia (CSDD) , Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12; Change in anxiety level (HADS-Anxiety Subscale) , Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12; Change in heart rate , Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12); Change in subjective well-being using a self-reported analog scale , Immediately before and immediately after each SMT session, three times per week for 12 weeks (36 sessions total); Change in heart rate variability (HRV) , Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12); Change in skin conductance , Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12); Change in oxygen saturation (SpO₂) , Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12); Change in salivary cortisol concentration , Immediately before and immediately after Session 1 (Baseline), and immediately before and immediately after Session 36 (Week 12). Brief summary: This randomized, controlled, longitudinal clinical trial investigates the effects of Snoezelen Multisensory Therapy (SMT) as an adjunct to standard therapy (ST) in older adults with dementia. Sixty-three participants with mild to moderate cognitive impairment and behavioral and psychological symptoms of dementia (BPSD) will be recruited from the Center for Older Adults Lucija (Slovenia). Participants will be randomized into two groups: control (ST) and experimental (ST + SMT). SMT will be administered 3 times per week for 12 weeks. Primary outcomes include changes in agitation (CMAI), depression (CSDD), anxiety (HADS), physiological indicators (heart rate, HR variability, SpO2, skin conductance, salivary cortisol), and frequency of psychiatric medication use. Subjective well-being will also be tracked before and after each session.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.